INDBInternet News Database 2.5 Updated just now · 297 sources Show or hide images Light or dark

FDA Rejects Promising Lung Cancer Drug Despite 48% Reduction in Risk of Disease Progression or Death

Save Like Comments Compare coverage

Summary

The FDA has rejected Summit Therapeutics' ivonescimab lung cancer treatment, saying trial data did not sufficiently prove patients lived longer despite a 48% lower risk of progression or death.

Description from Ibtimes.

Who is covering this

  1. Ibtimes Center Factuality: Mostly factual GB
    FDA Rejects Promising Lung Cancer Drug Despite 48% Reduction in Risk of Disease Progression or Death

    The FDA has rejected Summit Therapeutics' ivonescimab lung cancer treatment, saying trial data did not sufficiently prove patients lived longer despite a 48% lower risk of progression or death.

Comments

Comments need JavaScript.